Skip to main content
. Author manuscript; available in PMC: 2014 Jun 1.
Published in final edited form as: Prostate Cancer Prostatic Dis. 2013 Jan 8;16(2):10.1038/pcan.2012.49. doi: 10.1038/pcan.2012.49

Figure 1.

Figure 1

T cells can be engineered to recognize and kill prostate cancer cells expressing Muc1. (a) Shows the retroviral vector map of the CAR-Muc1 construct. (b) Shows a schematic representation of the CAR-Muc1 construct on the surface of transgenic T cells. (c) Shows transduction efficiency of CAR-Muc1 transduced T cells from a representative donor as evaluated by flow cytometry using an antibody directed against the CH2CH3 region of the retroviral construct. (d) Shows that CAR-Muc1 T cells kill the Muc1-expressing prostate cancer cell lines PC3 and DU145, as well as CAPAN1 (pancreatic cancer cell line) and MCF7 (breast cancer cell line), both of which also express Muc1, with negligible activity against Muc1-negative 293T cells. Cytotoxic activity was evaluated in a standard 51Cr-release assay, and results are shown at an E:T ratio of 40:1. Data represent the mean±s.d. of four donors.